New hope for aggressive lymphoma: trial tests Dual-Attack therapy
NCT ID NCT06863402
Summary
This study is testing a new combination of two drugs, nemtabrutinib and pembrolizumab, for patients with Richter transformation, a fast-growing type of lymphoma. The goal is to see if using these drugs together is safe and can shrink or control the cancer. The trial will enroll about 32 adults whose cancer has progressed or who cannot receive standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.